Amphetamine News and Research RSS Feed - Amphetamine News and Research

Quest Diagnostics analysis shows workforce drug use in U.S. reaches 10-year high

Quest Diagnostics analysis shows workforce drug use in U.S. reaches 10-year high

Following years of declines, the percentage of employees in the combined U.S. workforce testing positive for drugs has steadily increased over the last three years to a 10-year high, according to an analysis of nearly 11 million workforce drug test results released today by Quest Diagnostics, the world's leading provider of diagnostic information services. [More]
Study finds rising trends in marijuana use among college students

Study finds rising trends in marijuana use among college students

College student marijuana use continues its nearly decade-long increase, according to the most recent national Monitoring the Future study. [More]
New mice study identifies trick to enhance memories

New mice study identifies trick to enhance memories

Imagine if playing a new video game or riding a rollercoaster could help you prepare for an exam or remember other critical information. [More]
Scientists use animal model to gain better understanding of cocaine addiction

Scientists use animal model to gain better understanding of cocaine addiction

Scientists at Wake Forest Baptist Medical Center are one step closer to understanding what causes cocaine to be so addictive. The research findings are published in the current issue of the Journal of Neuroscience. [More]
Appetite hormone CART helps increase insulin secretion, reduce glucagon production

Appetite hormone CART helps increase insulin secretion, reduce glucagon production

The study shows that the appetite hormone CART not only controls the sensation of satiety, but it also helps increase insulin secretion and decrease glucagon production. [More]
Neos announces U.S. launch of Adzenys XR-ODT for ADHD

Neos announces U.S. launch of Adzenys XR-ODT for ADHD

Neos Therapeutics, Inc., a pharmaceutical company with a late‐stage pipeline of innovative extended-release (XR) product candidates for the treatment of attention-deficit/hyperactivity disorder (ADHD), today announced that Adzenys XR-ODT™ is in distribution channels and is now available to prescribe for patients with ADHD in the United States. [More]
Heavy marijuana use may lead to lower dopamine release in the brain

Heavy marijuana use may lead to lower dopamine release in the brain

In a recent study, researchers found evidence of a compromised dopamine system in heavy users of marijuana. Lower dopamine release was found in the striatum - a region of the brain that is involved in working memory, impulsive behavior, and attention. Previous studies have shown that addiction to other drugs of abuse, such as cocaine and heroin, have similar effects on dopamine release, but such evidence for cannabis was missing until now. [More]
ADHD stimulant drugs may lower bone density in children and adolescents

ADHD stimulant drugs may lower bone density in children and adolescents

Children and teenagers who take stimulant drugs to treat attention-deficit hyperactivity disorder (ADHD) may have lower bone density than their peers who do not take these medications, a new study finds. [More]
AMRI's net revenues increase $126.4M to 46% in fourth quarter 2015

AMRI's net revenues increase $126.4M to 46% in fourth quarter 2015

AMRI today reported financial and operating results for the fourth quarter and full year ended December 31, 2015 and provided an outlook for 2016. [More]
Misuse of Adderall drug rising among young adults, research suggests

Misuse of Adderall drug rising among young adults, research suggests

While the number of prescriptions for the stimulant Adderall has remained unchanged among young adults, misuse and emergency room visits related to the drug have risen dramatically in this group, new Johns Hopkins Bloomberg School of Public Health research suggests. [More]
Drug use remains stable among teens, MTF survey shows

Drug use remains stable among teens, MTF survey shows

The 2015 Monitoring the Future survey (MTF) shows decreasing use of a number of substances, including cigarettes, alcohol, prescription opioid pain relievers, and synthetic cannabinoids ("synthetic marijuana"). Other drug use remains stable, including marijuana, with continued high rates of daily use reported among 12th graders, and ongoing declines in perception of its harms. [More]

Biophor receives FDA 510(k) clearance for distribution of seventh oral fluid screening assay

Biophor Diagnostics, Inc. announces that it has received FDA 510(k) clearance for sale and distribution of its seventh oral fluid screening assay based on the RapidFRET IVD Platform technology. This clearance completes the company's flagship panel for drugs of abuse screening in oral fluid. [More]
Glowing protein may replace fiber optic cable as light source in optogenetics research

Glowing protein may replace fiber optic cable as light source in optogenetics research

Optogenetics has taken neuroscience by storm in recent years because the technique allows scientists to study the brain conveniently in animals, activating or inhibiting selected groups of neurons at the flip of a switch. Most often, scientists use a fiber optic cable to deliver light into the brain. [More]
One in every 17 college students smokes marijuana on daily or near-daily basis

One in every 17 college students smokes marijuana on daily or near-daily basis

Daily marijuana use among the nation's college students is on the rise, surpassing daily cigarette smoking for the first time in 2014. [More]
AMRI’s total revenue increases $89.5 million to 31% in second quarter 2015

AMRI’s total revenue increases $89.5 million to 31% in second quarter 2015

AMRI today reported financial and operating results for the second quarter ended June 30, 2015. "We are very pleased to present another strong financial quarter, with all our divisions achieving excellent results," said William S. Marth, AMRI's president and chief executive officer. "Notably, recent acquisitions, combined with the cost reduction initiatives and efficiency efforts we've made to date, are contributing to continued strong contract margin performance. [More]
Ironshore partners with Restore Health to participate in HLD-200 clinical trial to treat ADHD

Ironshore partners with Restore Health to participate in HLD-200 clinical trial to treat ADHD

Ironshore Pharmaceuticals & Development, Inc. has signed an agreement with Restore Health, a company specializing in personalized medicine, to participate in the fulfillment of a double-blind clinical trial, designed to evaluate the safety and efficacy of HLD-200, a new drug in development to treat Attention-deficit/hyperactivity disorder (ADHD). [More]
New study examines how reasons for illicit marijuana use relate to use of other drugs

New study examines how reasons for illicit marijuana use relate to use of other drugs

Marijuana is the most prevalent drug in the U.S. Approximately 70% of the 2.8 million individuals who initiated use of illicit drugs in 2013 reported that marijuana was their first drug. [More]
Amphetamine-based drug Evekeo effective in treating ADHD symptoms in children

Amphetamine-based drug Evekeo effective in treating ADHD symptoms in children

The amphetamine-based drug Evekeo, given once or twice daily to children 6-12 years of age, is effective in treating attention-deficit/hyperactivity disorder (ADHD) symptoms and improving performance in a laboratory classroom setting, according to the results of a new study published in the Journal of Child and Adolescent Psychopharmacology, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. [More]
New technology can detect illegal drugs from a single fingerprint

New technology can detect illegal drugs from a single fingerprint

An innovative technology pioneered by Sheffield Hallam University academics can detect the presence of a range of illegal and designer drugs from a single fingerprint, which could be a valuable new tool in bringing drug dealers and other criminals to justice. [More]
FDA accepts Tris Pharma's Dyanavel XR NDA for review

FDA accepts Tris Pharma's Dyanavel XR NDA for review

Tris Pharma, Inc. announced that U.S. Food and Drug Administration has accepted for review its New Drug Application ("NDA") for Dyanavel XR (amphetamine) CII, an Extended-Release Oral Suspension. [More]
Advertisement
Advertisement